sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks Cabozantinib s-malate

Cabozantinib s-malate

CAS No.:
1140909-48-3
Catalog Number:
AG000AJ8
Molecular Formula:
C32H30FN3O10
Molecular Weight:
635.5931
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
98%(HPLC)
In Stock USA
United States
$141
- +
Product Description
Catalog Number:
AG000AJ8
Chemical Name:
Cabozantinib s-malate
CAS Number:
1140909-48-3
Molecular Formula:
C32H30FN3O10
Molecular Weight:
635.5931
MDL Number:
MFCD20923480
IUPAC Name:
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid
InChI:
InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
InChI Key:
HFCFMRYTXDINDK-WNQIDUERSA-N
SMILES:
OC(=O)C[C@@H](C(=O)O)O.COc1cc2nccc(c2cc1OC)Oc1ccc(cc1)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F
UNII:
DR7ST46X58
Properties
Complexity:
924  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0
Exact Mass:
635.192g/mol
Formal Charge:
0
Heavy Atom Count:
46  
Hydrogen Bond Acceptor Count:
12  
Hydrogen Bond Donor Count:
5  
Isotope Atom Count:
0
Molecular Weight:
635.601g/mol
Monoisotopic Mass:
635.192g/mol
Rotatable Bond Count:
11  
Topological Polar Surface Area:
194A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Expert review of clinical pharmacology 20160101
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine 20151105
Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20140101
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck 20120501
Novel molecular targets for the therapy of castration-resistant prostate cancer. European urology 20120501
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer discovery 20120301
c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 20111201
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Molecular cancer therapeutics 20111201
Novel therapies for metastatic castrate-resistant prostate cancer. Journal of the National Cancer Institute 20111116
Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs of today (Barcelona, Spain : 1998) 20111101
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer research 20110715
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110701
Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 20110615
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. The Journal of clinical endocrinology and metabolism 20110601
XL184 (cabozantinib) for medullary thyroid carcinoma. Expert opinion on investigational drugs 20110301
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. Endocrine journal 20110101
Novel treatment of medullary thyroid cancer. Current opinion in endocrinology, diabetes, and obesity 20091001
Properties